- Home
- Equipment
- australasia
- phase 1 clinical
Refine by
Phase 1 Clinical Equipment Supplied In Australasia
9 equipment items found
Manufactured by:Magellan based inBox Hill North, AUSTRALIA
Our product MAG200 has successfully completed Phase I/II of a clinical trials on the use of allogeneic (donor) off-the-shelf stem cell therapy for OA. The pivotal Phase III trial is planned to commence 2023. ...
by:Starpharma Holdings Limited based inMelbourne, AUSTRALIA
VivaGel® BV is available for sale under the brand names Betafem® BV Gel (UK), Betadine BVTM (Europe), BetadineTM BV Gel (Asia) and Fleurstat BVgel (Australia & New Zealand). VivaGel® has been developed for the treatment of BV and prevention of recurrent bacterial vaginosis (BV). BV is caused by an imbalance of the normal vaginal bacterial microflora, with healthy bacteria (e.g. ...
Manufactured by:PolyActiva Pty Ltd. based inParkville, AUSTRALIA
Being developed to reduce IOP caused by Open-Angle Glaucoma & Ocular Hypertension. Clinical Investigation Stage: Phase ...
Manufactured by:PolyActiva Pty Ltd. based inParkville, AUSTRALIA
Being developed to reduce the risk of Endophthalmitis following ocular (cataract) surgery. Clinical Investigation Stage: Phase ...
Manufactured by:ARANZ Medical Limited based inChristchurch, NEW ZEALAND
A proven wound assessment and management solution for both clinical practice and clinical research. ...
Manufactured by:NeuroScientific Biopharmaceuticals Ltd. based inCottesloe, AUSTRALIA
EmtinB is the lead candidate that has shown to closely mimic the neuroprotective and neuroregenerative ability of MT-II. ...
Manufactured by:Mesoblast Ltd. based inMelbourne, AUSTRALIA
Revascor is a Phase 3 product candidate being developed as a treatment for both advanced and end-stage chronic heart failure ...
by:Atmo Biosciences based inBox Hill, AUSTRALIA
A safe and accurate way of measuring the concentration of various gases at the source of production in the gastrointestinal tract (GI tract) in ...
Manufactured by:BioDiem Ltd. based inSouth Melbourne, AUSTRALIA
A core technology advantage: Live Attenuated Influenza Virus (LAIV) vaccine. BioDiem’s lead asset is the Live Attenuated Influenza Virus (LAIV) vaccine technology. Our LAIV vaccine licensing business involves out-licensing of the company’s platform technology to vaccine manufacturers for the production of intranasal vaccines for the prevention of seasonal and pandemic ...